Clinical Trials for Locally Advanced Pancreatic Cancer

[Ilsa]

I came across this information while reading my husband's sports-related message board. I hope it helps someone.
Ilsa

http://www.genvec.com/ This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry.

Purpose: The primary purpose of this study is to assess the safety and effectiveness of TNFerade™ Biologic when administered concurrently with 5-FU and radiation therapy as first-line treatment of unresectable locally advanced pancreatic cancer.

TNFerade™ is a replication deficient adenovirus vector containing the gene for TNF-alpha controlled by a chemoradiation inducible promoter. This allows the expression of TNF-alpha to be greatest in the area receiving radiation. TNF-alpha is a cytokine that has been shown to have potent anti-cancer activities but, due to systemic toxicity, could not be delivered at effective doses. TNFerade™ Biologic is a novel way of selective delivery of TNF-alpha to tumor cells.

TNFerade™ Biologic will be injected during five weekly injection sessions, concomitant with radiation and 5-FU. TNFerade™ Biologic will be administered by direct intratumoral injection using a percutaneous approach (PTA) or endoscopic ultrasound (EUS).


Locations of clinical trials:

USA

Mobile, AL

Tucson, AZ

La Jolla, CA

Los Angeles, CA

Los Angeles, CA

Orange, CA

San Francisco, CA

Denver, CO

Washington, DC

Tampa, FL

Tampa, FL

Atlanta, GA

Chicago, IL

Chicago, IL

Olympia Fields, IL

Indianapolis, IN

Lexington, KY

Alexandria, LA

Boston, MA

Baltimore, MD

Detroit, MI

Kansas City, MO

St. Louis, MO

Greenville, NC

New York, NY

New York, NY

Cleveland, OH

Portland, OR

Portland, OR

Greenville, SC

Dallas, TX

Dallas, TX

Houston, TX

Richmond, VA

Seattle, WA

Marshfield, WI

Milwaukee, WI